The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.
Walter Fiedler
Consultant or Advisory Role - Novartis; Pfizer
Research Funding - Novartis; Pfizer
Cristiana Sessa
No relevant relationships to disclose
Luca Gianni
Consultant or Advisory Role - AstraZeneca; BioScience; Boehringer Ingelheim; Celgene; Genentech/Roche; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical
Sara Cresta
No relevant relationships to disclose
Henning Schulze-Bergkamen
No relevant relationships to disclose
Jens Weidmann
No relevant relationships to disclose
Sara De Dosso
No relevant relationships to disclose
Anna Tessari
No relevant relationships to disclose
Marc Oliver Salzberg
Consultant or Advisory Role - Glycotope GmbH
Hans Baumeister
Employment or Leadership Position - Glycotope GmbH
Stock Ownership - Glycotope GmbH
Antje Danielczyk
Employment or Leadership Position - Glycotope GmbH
Stock Ownership - Glycotope GmbH
Bruno Dietrich
Employment or Leadership Position - Glycotope GmbH
Johannes Nippgen
Employment or Leadership Position - Glycotope GmbH
Steffen Goletz
Employment or Leadership Position - Glycotope GmbH
Stock Ownership - Glycotope GmbH